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Background. Cardiovascular disease is the principal cause of mortality in older individuals, and more than 80% of deaths due
to coronary heart disease or stroke occur in patients over 65 years of age. Hyperlipidemia is one of the main modiﬁable risk
factorsforcardiovasculardisease.Currentguidelinesrecommendtheuseofstatinstoreducelow-densitylipoproteincholesterolto
appropriatetargetsbasedonanindividual’scardiovascularrisk,andclearlystatethatolderageshouldnotbeabarriertotreatment.
Despiteextensiveevidencedemonstratingclearbeneﬁtwithstatintherapyinolderindividuals,thispopulationremainschronically
undertreated. Scope. This paper provides an overview of the current evidence available regarding the eﬃcacy and safety of statin
therapytoreducecardiovascularriskinolderpatients.Weusehypotheticalcasestudiestoaddresssomeofthequestionsfrequently
posed by physicians responsible for the cardiovascular health of older patients. Conclusions. Various factors may account for the
failure to provide appropriate treatment, including a lack of awareness of clinical beneﬁts and perceived safety issues. However,
if current guidelines are followed and older patients treated to appropriate LDL-C goals, the likelihood of cardiovascular events
will be reduced in this high-risk population. Employing an evidence-based approach to the management of cardiovascular risk in
older patients is likely to yield beneﬁts in terms of overall cardiovascular burden.
1.Introduction
The incidence of cardiovascular (CV) events increases shar-
ply with age, and the prevalence of CV disease and concomi-
tant risk factors is signiﬁcantly higher in older individuals
[1]. Cardiovascular disease is the principal cause of death
in older patients, in that well over 80% of deaths due to
coronary heart disease (CHD) or stroke occur in individuals
65 years of age or older [2]. Prevention of CV disease and
recurrent CV events in older individuals remains a major
challenge.
Hyperlipidemia isoneofthemainmodiﬁableriskfactors
for CV disease, and current guidelines recommend statin
therapy to reduce low-density lipoprotein cholesterol (LDL-
C) levels to appropriate targets based on the individual’s
level of CV risk [3–6]. The pharmacokinetic proﬁles of
statins have been shown to diﬀer little in young and older
subjects. What variations that may exist are not considered
clinically relevant, and dose adjustments based on age are
not advocated [7–9]. However, while lipid-lowering therapy
is widely underutilized in middle age, there is considerably
more clinical inertia associated with the use of statins in
older patients. This occurs despite extensive evidence of a
reduction in CV risk associated with statin treatment in this
patient age group.
Historically, data from trials such as the Scandinavian
Simvastatin Survival Study (4S) [10], the Cholesterol and
Recurrent Events (CARE) trial [11] and the Long-term
Intervention with Pravastatin in Ischemic Disease (LIPID)
study [12] showed that statin therapy for secondary pre-
vention was comparably eﬀective in older patients and their
younger counterparts. Subanalyses of these studies designed
to compare the eﬀects of statin therapy in older and younger
patients indicated that similar or greater beneﬁt in mortality,
major CV, events and stroke was obtained in patients who
were 65 years of age or older at the time of enrolment
[13–15]. Given the increased likelihood of CV events in
older patients, a similar relative risk reduction with statin2 Current Gerontology and Geriatrics Research
therapyconfersagreaterabsolutebeneﬁt.IntheCAREstudy,
for instance, coronary death was reduced from 10.3% to
5.8% in patients over 65 years of age, whereas in younger
patients no such absolute risk reduction was observed [13].
Likewise, in patients aged 65 to 75 years, stroke was reduced
from 7.3% to 4.5% with pravastatin treatment, but in
younger patients only a 0.4% absolute risk reduction was
observed.DatafromtheCardiovascularHealthStudy(CHS),
an observational study which included largely a primary
prevention population, showed a 56% reduction in CV
events and a 44% reduction in all-cause mortality in patients
65 years or older who received statin therapy compared with
those who did not receive statins [16]. Subsequent studies
such as the Heart Protection Study (HPS) [17] and the lipid-
lowering arm of the Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT-LLA) [18] have shown similar results. Studies
designed speciﬁcally to address older patients, such as the
Prospective Study of Pravastatin in the Elderly at Risk
(PROSPER) [19] also showed a signiﬁcant reduction in the
rate of CV events. The beneﬁt of statin therapy for secondary
prevention in older patients has recently been conﬁrmed by
a metaanalysis of nine clinical trials [20], which concluded
that the reduction in mortality associated with statin therapy
inolderpatientswasmuchgreaterthanpreviouslyestimated.
A metaanalysis of 10 randomized clinical trials that enrolled
70388 people with CV risk factors but without established
CV disease showed comparable beneﬁt in those younger and
older than age 65: improved survival and reduction in the
riskofmajorCVevents[21]. Finally, the beneﬁts of intensive
statin regimens to achieve substantial LDL-C reductions
are clearly maintained in patients aged over 65 years [22,
23]. Analysis of Kaplan-Meier plots to assess the eﬀect of
treatmentonCVeventsovertimesuggeststhatinmanycases
beneﬁt may be obtained relatively soon after initiation of
statin therapy [22–24]; given the higher incidence of events
in an older population, beneﬁts are likely to be even more
apparent than in younger individuals.
The data on the beneﬁt of statin therapy in older
patients are compelling and support the assertion in the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) guidelines that age should not
be a barrier to such treatment [3, 4]. Nevertheless, older
patients commonly remain untreated or undertreated [25,
26]. Following the update to NCEP ATP III in 2004, analysis
showed that among very-high-risk older individuals, 85% of
patientsnewlyinitiatedtostatintherapyand78%ofongoing
usersreceivedminimal-guidelinetherapy[26].Furthermore,
<50% of very-high-risk older patients attained the optional
goal of <70mg/dL.
A number of factors may contribute to this failure to
provide appropriate statin therapy. First, despite evidence of
clearbeneﬁtinolderpatients,theproportionofsuchpatients
enrolled in pivotal statin trials has often been relatively
low, particularly those above 70 years of age (Table 1). The
lower proportion of older patients in these studies may
lead to an inaccurate perception regarding the strength of
the data available on statin use in older age individuals,
with uncertainty arising among physicians and payers, as
well as older patients and their families. Older patients
may also be expected to have diminished liver and kidney
function, small stature and general frailty. As a result of such
generalization, high-dose statins are commonly perceived as
more likely to cause adverse events in older patients, despite
a lack of evidence to support such an assertion, and this
may contribute to the undertreatment of hyperlipidemia
in this patient group. In addition, older patients are often
prescribed multiple medications and the potential for drug-
drug interactions that could limit the use of certain statins
may be of particular concern. All these factors may begin
to explain why older patients are less likely to be prescribed
statins and, even when prescribed, less likely to be titrated to
doses suﬃcient to achieve LDL-C targets [25].
To address the problem of undertreatment in older
patients, physicians must tailor treatment based on the
overall CV risk of each individual, regardless of age. Appro-
priate management involves balancing the need to treat
to guideline-based LDL-C targets with the general safety
concerns that inﬂuence the treatment of older patients and
an assessment of the general health and prognosis of each
individual. In other words, age should not constitute a
barrier to appropriate statin treatment for the reduction
of CV risk. The age-associated increase in CV risk is
reﬂected in the inclusion of age as a signiﬁcant variable in
determining the Framingham risk score, which rises from
middle age onwards [3, 27]. As stated in the NCEP ATP
III guidelines, older age reﬂects the cumulative exposure
to atherogenic risk factors [3]. However, an individual’s
overall CV risk is inﬂuenced by numerous other factors
[28, 29]. Consequently, arbitrary decisions to alter treatment
approaches in patients above a given age—whether 65, 75,
or even 85 years—are inappropriate. Rather, age can be
considered as simply another risk factor to be taken into
account along with other factors relating to CV risk, general
health, safety, and prognosis considered concomitantly in
identifying the most appropriate treatment when assessing
strategies for the prevention and treatment of CV disease.
In this paper, hypothetical case studies are used to
illustrate the assessment of CV risk in an older patient
and to incorporate the appropriate use of guidelines and
CV outcomes trial evidence to assist the treating physician’s
decision-making process. We attempt to answer the fre-
quently asked questions of clinicians who manage the CV
health of older patients.
2.ClinicalVignettes
2.1. Patient 1—Acute Coronary Syndrome. This 76-year-old
white female is 5 3   tall and weighs 142 lbs; her body mass
index (BMI) is 25.2. She is a nonsmoker with no history
of diabetes. She was hospitalized 2 weeks previously with
a non-ST-elevation myocardial infarction (NSTEMI) and
underwent a percutaneous coronary intervention (PCI) with
bare-metal stent placement. During the hospitalization she
received aspirin 325mg/d, clopidogrel 75mg/d, metoprolol
50mg/d, lisinopril 20mg/d, and atorvastatin 80mg/d. There
was no heart failure or serious arrhythmia. At a cardiol-
ogy follow-up appointment after discharge, it was found
that the patient was receiving aspirin 81mg/d, clopidogrelCurrent Gerontology and Geriatrics Research 3
Table 1: Proportions of older patients enrolled in pivotal statin trials.
Study Characteristics
Age at enrolment
≥65 years ≥70 years
Scandinavian Simvastatin
Survival Study (4S) [10]
Simavastatin versus placebo
Patients aged 35–70 years
n = 4444
23% —
Cholesterol and Recurring Events
(CARE) Trial. Lewis et al. [13]
Pravastatin versus placebo
Patients aged 21–75 years
n = 4059
31% 12%
Heart Protection Study (HPS)
[17]
Simavastatin versus placebo
Patients aged 40–80 years
n = 20536
52% 28%
Treating to New Targets (TNT).
Wenger et al. [22]
Atorvastatin 80 mg versus
10mg Patients aged 35–75
years
n = 10001
38% 18%
75mg/d, metoprolol 50mg/d, lisinopril 20mg/d, and had
been changed by her primary care physician to simvastatin
20mg/d. Laboratory studies indicated the following: total
cholesterol (TC) = 180mg/dL, LDL-C = 97mg/dL, high-
densitylipoproteincholesterol(HDL-C) =39mg/dL,triglyc-
erides (TGs) = 154mg/dL, and creatinine = 1.2mg/dL.
This patient with a recent acute coronary syndrome
(ACS) is at very high risk of recurrent CV events. Both
NCEP ATP III [4] and American College of Cardi-
ology/American Heart Association (ACC/AHA) unstable
angina/NSTEMI guidelines [5] support the optional LDL-
Ct a r g e to f<70mg/dL. However, the patient’s current statin
regimen (simvastatin 20mg/d), initiated by her primary care
physician following discharge, has not achieved this goal,
and titration to a higher dose likely would be insuﬃcient
to achieve the LDL-C target or oﬀer clear beneﬁt in terms
of CV outcomes. It is unclear why the hospital regimen
of atorvastatin 80mg/d was not continued. Based on the
percentage reduction in LDL-C achieved with the current
regimen (Table 2), the patient’s unmedicated LDL-C would
be expected to be approximately 156 mg/dL. Consequently,
to achieve a target of <70mg/dL a 56% reduction is required.
As shown in Table 2, this likely would not be achieved
with the highest dose of simvastatin (80mg/d). Statin dose
response tends to obey the rule of sixes, such that the greatest
lipid-lowering response is obtained at the starting dose,
while incremental doubling of the statin dose leads to an
approximately 6% additive reduction in LDL-C. Titration
to even the highest dose of simvastatin would not also be
expected to provide additional CV beneﬁt [30]a n dm a y
be associated with a higher risk of myopathy [31]. This
highlights the importance of appropriate choice of statin
regimen, considering the predicted potency of statin dose
andensuringthatanappropriatedosetoachievethepatient’s
LDL-C target is employed from the outset. An evidence-
based approach to treatment of this patient supports the use
of intensive statin therapy.
A statistically signiﬁcant beneﬁt of atorvastatin 80mg/d
to prevent major CV events in patients with ACS has been
showninboththePravastatinorAtorvastatinEvaluationand
Infection Therapy—Thrombolysis in Myocardial Infarction
22 (PROVE IT—TIMI 22) [33], and Myocardial Ischemia
Reduction with Aggressive Cholesterol Lowering (MIRACL)
[34] studies when compared with standard therapy (pravas-
tatin 40mg/d) or placebo, respectively. Analysis of patients
at least 70 years of age in PROVE IT-TIMI 22 [35]a n dc o m -
parison of patients aged <65 or ≥65 years in MIRACL [36]
showed that high-dose atorvastatin was as safe and eﬀective
in older as in younger patients. Also, a subanalysis of the
Treating to New Targets (TNT) study showed that treatment
with atorvastatin 80mg continued to reduce the risk of any
recurrent CV event over time compared with atorvastatin
10mg in patients 65 years of age or older [37], suggesting
that continuation of high-dose statin therapy would have
sustained beneﬁt in this patient. The cardiologist therefore
determined that atorvastatin 80mg/d should be reinstated
and treatment continued with aspirin 81mg/d, clopidogrel
75mg/d, metoprolol 50mg/d and lisinopril 20mg/d.
In subsequent years, this patient would require ongoing
followup for chronic CHD. The LDL-C targets speciﬁed
in the NCEP ATP III guidelines for such patients remain
similar (<100mg/dL with an optional target of <70mg/dL).
Although a more moderate statin dose could be suﬃcient
to achieve a goal of <100mg/dL, data on clinical outcomes
suggest that intensive lipid-lowering to achieve the optional
target will have greater beneﬁt without increasing the
likelihood of adverse events. The TNT study showed a
relative risk reduction of 19% for major CV events with
atorvastatin 80mg/d versus atorvastatin 10mg/d in stable
CHD patients 65 years of age or older, with no notable
diﬀerence in withdrawal from therapy due to adverse events.
A subanalysis of patients aged 65 to 78 years in the
Aggressive Lipid-Lowering Initiation Abates New Cardiac
Events (ALLIANCE) study also showed a signiﬁcant beneﬁt
of titration to more intensive statin therapy [23]. This
study compared the patient’s usual care (continuation of
baseline therapy with changes and laboratory studies as
directed by their treating physicians) with titration to a mean
atorvastatin dose of 36.5 ± 27.4mg/d (59.9% were titrated to
at least 40mg/d and 38.7% to 80mg/d), resulting in a 27%4 Current Gerontology and Geriatrics Research
Table 2: Percentage reductions in low-density lipoprotein choles-
t e r o lw i t hd i ﬀerent statin doses (Adapted from Alexander et al.
[32]).
Statin LDL-C reduction, %
Pravastatin
10 22
20 32
40 34
80 37
Lovastatin
10 21
20 27
40 31
80 42
Simvastatin
52 6
10 30
20 38
40 41
80 47
Atorvastatin
10 39
20 43
40 50
80 60
Ezetimibe/simvastatin
10/10 45
10/20 52
10/40 55
10/80 60
Rosuvastatin
54 5
10 52
20 55
40 63
reduction in the relative risk of major CV events. Similarly,
in the Study Assessing Goals in the Elderly (SAGE) [24],
intensive atorvastatin therapy in patients aged 65 to 85 years
reduced major CV events and all-cause mortality to a greater
extent than moderate statin therapy with pravastatin. Taken
together these ﬁndings support continuation of intensive
statin therapy to achieve the optional LDL-C target of
<70mg/dL.
2.2. Patient 2—High-Risk Older Patient with Comorbidities.
This 73-year-old African American male is 5 10
   tall and
weighs 216 lbs; his BMI is 31.0. He has a history of CHD
(coronary artery bypass graft [CABG] 5 years previously)
and mild-to-moderate chronic kidney disease (CKD), with
anestimatedglomerularﬁltrationrate(eGFR)of52mL/min.
Hewasdiagnosedwithtype2diabetesatage65yearsandhas
metabolic syndrome according to the International Diabetes
Federation deﬁnition [38], further increasing his CV risk.
He discontinued cigarette smoking 5 years ago and has a
family history of CV disease. There is no current angina
or congestive heart failure. He has a blood pressure (BP)
of 133/77mmHg (medicated), TC = 178mg/dL, LDL-C =
117mg/dL, HDL-C = 44mg/dL, TGs = 180mg/dL, HbA1c
= 7.3%, fasting glucose = 150mg/dL, and serum creatinine =
1.4mg/dL.
The patient had reasonable exercise tolerance prior to
an episode of pneumonia, for which he was admitted to
the emergency department, treated with azithromycin and
rocephin,anddischargedwithaprescriptionforaquinolone.
Prior to admission he was receiving atorvastatin 10mg/d,
but the physician treating his pneumonia discontinued statin
treatment for the duration of the antibiotic therapy. The
primary care physician saw the patient for a follow-up
appointmentafterdischargeandcompletionoftheantibiotic
course. Current medications are aspirin 81mg/d, metformin
1000mg/d, ramipril 10mg/d, and carvedilol 25mg twice
daily.
Although it is not unreasonable to discontinue statin
therapy during treatment with a macrolide antibiotic, this
should be a temporary discontinuation (drug holiday) and
statins should be reinstated following completion of antibi-
otic therapy. In this high-risk patient with concomitant risk
factors, the statin regimen prior to the episode of pneumonia
was inadequate to reach his target LDL-C levels and should
be reassessed. The updated NCEP ATP III guidelines indicate
that such a patient should be treated to a LDL-C goal of
<100mg/dL with an optional goal of <70mg/dL [4]. A
higher dose of a potent statin may therefore be required.
Strong evidence supporting intensive statin therapy in such
a patient comes primarily from subanalyses of the TNT
trial. Compared with patients receiving atorvastatin 10mg,
intensive therapy with atorvastatin 80mg yielded signiﬁcant
beneﬁts in TNT subjects who had either diabetes [39], CKD
[40], or both [41]. These analyses also found no diﬀerences
in the rate of adverse events compared with the total group
of patients in TNT. The results of the TNT subanalysis in
older patients [22] provide further support for the use of
atorvastatin 80mg in this patient. High-dose statin therapy
may also beneﬁt this patient by improving kidney function.
Among patients from the TNT study with diabetes and
CKD,thosereceivingatorvastatin80mgshowedsigniﬁcantly
greater improvement in kidney function than those treated
withatorvastatin10mg(meanchangeineGFRfrombaseline
withatorvastatin10mgversus80mg:0.5versus2.6mL/min)
[41]. Weight control should also be assessed and therapeutic
lifestyle change prescribed through dietary improvement
and regular exercise. Once the patient’s LDL-C goal has
been reached, if the TG levels are not <150mg/d it may be
appropriate to consider reducing his TG levels with addition
of omega-3 fatty acids, niacin, or fenoﬁbrate.
2.3. Patient 3—Primary Prevention. This 66-year-old male is
5 7   tallandweighs179lbs;hisBMIis28.Heisanonsmoker
and is receiving treatment for hypertension. He has a BP of
139/85mmHg, TC = 201mg/dL, LDL-C = 119mg/dL, HDL-
C = 50.1mg/dL, TGs = 150mg/dL, and C-reactive protein
(CRP) = 4.2mg/L. The patient is very health conscious, hasCurrent Gerontology and Geriatrics Research 5
a good routine level of physical activity, and had his CRP
level measured, at his own request, following media coverage
of the Justiﬁcation for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER) study
[42]—the measurement was done only once at an oﬀ-site
laboratory. Although his serum LDL-C level is relatively low,
he has a Framingham risk score of 17%, and is therefore
classiﬁed as at moderately high risk. He is currently treated
with aspirin 81mg/d, lisinopril 20mg/d, and a thiazide
diuretic 25mg/d.
The ﬁndings of the ASCOT Blood Pressure Lowering
Arm (ASCOT-BPLA) highlighted the importance of BP
controlinreducingCVrisk[43].Inthatstudy,manypatients
remained hypertensive despite receiving antihypertensive
therapy prior to enrolment. Since this patient remains
hypertensive with his current treatment regimen, the dose
of lisinopril should be increased to 40mg/d. In addition,
the lipid-lowering arm of the ASCOT trial (ASCOT-LLA),
in which hypertensive patients with a fasting LDL-C of
≤251mg/dL were randomly assigned to treatment with
atorvastatin10mgorplacebo,showedasigniﬁcantreduction
in the risk of CV events with atorvastatin therapy [18].
Similar results were also obtained in a post hoc analysis
of the ASCOT-LLA which showed that atorvastatin 10mg
signiﬁcantly reduced the risk of CV events in patients 65
years of age or older [44]. Given the Framingham risk score
of this patient, current guidelines and clinical trial evidence
would support treating to an optional LDL-C goal of
<100mg/dL.Asthiscorrespondstoa16%reductioninLDL-
C, various lipid-lowering options are available (Table 2).
The results of the JUPITER trial further conﬁrmed the
beneﬁt of lipid-lowering in moderately high-risk initially
healthypatientsandsupportedtheneedtotreatsuchpatients
even more intensively. Compared with placebo, rosuvastatin
20mg/d led to a 43% reduction in the risk of major CV
events in patients with LDL-C <130mg/dL and persistently
elevated CRP (>2.0mg/dL) [42]. There was no diﬀerence in
the beneﬁt for patients aged <65 or ≥65 years. Although
the patient in this case study is comparable to subjects
enrolled in the JUPITER study, elevated CRP was only
documented in a single measurement. Since CRP is an
acute phase reactant and its concentration increases rapidly
in response to inﬂammation, the ﬁnding could easily be
explained by a variety of factors, including simple infection.
It would be necessary to assess CRP based on the average
of two independent measurements, as was done in the
JUPITERtrial.Nevertheless,whiletheresultsoftheJUPITER
trial are provocative, they have not been incorporated into
guidelines. The relevance of CRP levels is also currently
under consideration and it remains to be seen whether
this parameter will be included in future guidelines. This
patient should therefore receive treatment based on current
recommendations [4], to achieve the optional LDL-C goal of
<100mg/dL with an appropriate dose of statin. Importantly,
the rule of sixes should be taken into account (the greatest
lipid-lowering response is obtained at the initial statin
dose, while incremental doubling of the dose leads to an
approximately 6% additive reduction in LDL-C) and an
appropriate starting dose used to achieve this target without
a requirement for subsequent dose increase. However, if the
LDL-C goal is not achieved after 6 to 8 weeks, the statin
regimen should be changed accordingly.
2.4. Patient 4—Primary Prevention in an Ostensibly Heart-
Healthy Older Patient. This 80-year-old Caucasian male
continues to be an avid mountain climber and comes in
for a medical evaluation prior to his next climb. During the
examination he asks the physician if he should be taking
a statin. He is 6 0   tall, weighs 172 lbs, and has a BMI of
23.3. He is a nonsmoker with no history of diabetes, and his
only medication is aspirin 81mg/d. However, his father died
of a myocardial infarction at age 54, which has led him to
maintain a healthy lifestyle. He has a BP of 120/75mmHg,
TC = 190mg/dL, LDL-C = 140mg/dL, HDL-C = 49mg/dL,
and TGs = 120mg/dL.
Althoughthispatientseemshealthyandisveryactive,his
Framingham risk is 17%, primarily due to his advanced age,
indicating a moderately high risk of CV disease. Thus, even
in an apparently healthy patient, age continues to be a very
important risk factor. Although clinical trial data are scarce
for primary prevention in subjects of this age, on the basis
of risk, the NCEP ATP III update recommends an optional
LDL-C goal of <100mg/dL for this patient [4]. If the patient
werehypertensive,thisrecommendationwouldbesupported
by the ﬁndings of the ASCOT-LLA [18]. In that study,
patients had a mean baseline LDL-C just over 130mg/dL;
treatment with atorvastatin 10mg/d versus placebo led to
a signiﬁcant reduction in CV risk, and this eﬀect remained
apparent in patients aged over 65 years [44]. Likewise, were
the patient to have an elevated CRP, the results of the
JUPITER [42]t r i a lw o u l dh a v es o m eb e a r i n go nh i st r e a t -
ment. However, there have been no speciﬁc trials addressing
patients of this type. Thus, in the absence of new recom-
mendations, current guidelines should be followed and the
patient should be treated to an LDL-C goal of <130mg/dL
or an optional goal of 100mg/dL with an appropriate statin,
titrated to goal. To reach the optional goal, it would be
necessary to use a statin regimen that would allow at least
a 29% reduction in LDL-C (Table 2). Consequently, a variety
of options are available, including the use of generic statins.
3. Statin Therapy in Older Patients—Safety
and Adherence
A number of statin clinical trials and subanalyses have
shown that treatment-related adverse events are not more
common in older patients compared with their younger
counterparts. In the TNT study (n = 10001), the proportion
of patients aged ≥65 years (n = 3809) who experienced
treatment-related adverse events was comparable to that
observed in patients <65 years for both the 10mg and
80mg doses of atorvastatin [22]. In SAGE, which enrolled
only older participants (range: 65–85 years), a similar
proportion of patients experienced adverse events in the
atorvastatin 80mg and pravastatin 40mg treatment arms
[24]. As in other studies of high-dose statin regimens [45],
the frequency of elevated liver enzymes remained low overall6 Current Gerontology and Geriatrics Research
but elevated compared to less-intensive regimens (4.3%
of patients treated with atorvastatin 80mg versus 0.2%
of patients treated with pravastatin 40mg). Liver function
should be monitored in all patients treated with high-dose
statins. However, treatment decisions should be made on an
individual basis and concerns about hepatotoxicity should
not be an automatic barrier to intensive statin therapy to
achieve LDL-C targets in older patients. Similarly, myalgia
and myopathy appear to be associated with statin therapy,
but do not seem to be increased in older patients compared
with their younger counterparts [22, 24, 46].
The largest analysis of statin safety in older patients
reported to date included data pooled from 50 clinical trials
ofatorvastatintherapy[47].Inthatanalysis,5437patients65
years of age or older were found to have a low rate of serious
adverse events (≤1%) and there was little diﬀerence in the
proportion of patients who withdrew due to treatment-
relatedadverseeventsassociatedwithplacebooratorvastatin
treatment (2.1% versus 1.7%).
Elevated alanine transaminase or aspartate transaminase
levels were more common in patients treated with ator-
vastatin 80mg compared with placebo (3.2% versus 0.9%),
but speciﬁc musculoskeletal or liver abnormalities remained
rare (≤3%). A similar study involving a pooled analysis
of 3145 patients aged ≥75 years who received placebo or
atorvastatin 10–80mg in 45 completed randomized trials
demonstrated that the rate of adverse events did not increase
withhigherdosesofthedrugandwassimilarinatorvastatin-
treated patients and those who received placebo [48]. Thus,
currently available evidence suggests that the safety of statin
therapy remains similar in older and younger patients, even
with intensive lipid lowering.
Although age may not in itself represent a barrier to
intensive statin therapy, a large proportion of older patients
are receiving multiple medications for other conditions and
care should be taken to avoid drug-drug interactions. As an
example, older patients receiving concomitant amiodarone
may be at particularly high risk of myopathy when treated
with statins that are metabolized by CYP3A4 [49]. In
such patients, it may be preferable to use pravastatin or
rosuvastatin, as they are not metabolized by CYP3A4. Any
drugs that bind enzymes involved in statin metabolism may
be liable to alter statin levels and increase the risk of toxicity.
InthecaseoftheCYP3A4-metabolizedstatins,drugsinclude
verapamil and diltiazem, which may be used with care in
combination with low doses of those statins, or systemic
azole antibiotics such as itraconazole or ritonavir, which are
associated with a much higher risk of statin toxicity and
should not be used in combination with statins [50, 51]. The
possibility of drug interactions with warfarin should also be
taken into account [52], and where necessary, alternatives
such as atorvastatin considered [53]. In patients with mixed
dyslipidemia, use of fenoﬁbrate is preferable to gemﬁbrozil,
since fenoﬁbrate is not associated with signiﬁcant inhibition
of statin metabolism [54]. As in all patients, other possible
interactions with foodstuﬀso ro t h e rp r o d u c t sm u s tb et a k e n
into consideration. Grapefruit juice is suggested to be a risk
for statin toxicity through its inhibition of CYP3A4 [55],
but is likely to be clinically relevant only when consumed in
large quantities (>1.2L/d). St. John’s Wort has been shown
to reduce plasma concentrations of simvastatin [56].
Adherence to statin therapy is relatively poor among
all patients treated, but this phenomenon appears to be
especially true in primary prevention patients [57]a n d
older patients [57–59]. For example, a large cohort study
of patients aged ≥65 years found that adherence declined
according to risk—only 40.1% in ACS patients, 36.1% in
patients with chronic CHD, and 25.4% in those treated for
primary prevention [59]. Clearly, such low adherence results
in limited beneﬁt, such that it is important for primary care
physicians to monitor and encourage treatment adherence
carefullywhileensuringthatpatientsaretreatedtoguideline-
based goals. Progress towards LDL-C goals has a positive
impact on adherence to statin therapy [60–62]. However,
by exhibiting a greater tendency to arbitrarily withdraw
intensive statin therapy or failing to titrate to target LDL-
C levels in older patients, physicians may contribute to
undertreatment. Adherence to both simvastatin 20−40mg/d
and atorvastatin 80mg/d was generally very high (>80%)
in patients ≥65 years of age enrolled in the open-label
Incremental DEcrease through Aggressive Lipid Lowering
(IDEAL) study [46]. However, despite no diﬀerence in the
rate of adverse events, treatment withdrawal due to adverse
events was signiﬁcantly higher in patients randomized
to atorvastatin therapy. Since most patients had received
simvastatin prior to randomization, the authors of that
study interpreted the increased tendency to withdraw a
more potent statin dose as a possible reﬂection of greater
reluctance of physicians to continue high-dose statin therapy
in older patients. If treatment options are to be used
eﬀectively to reduce CV risk in an older patient population,
physicians must ensure that, while carefully monitoring the
progress of the individual patient, they follow appropriate
treatment guidelines and base their clinical decisions on
available evidence.
4. Conclusions
Age alone places older patients at increased risk of CV
disease, independent of the presence or absence of other
CV risk factors. Yet older individuals remain pervasively
undertreated with lipid-lowering drugs. Even when pre-
scribed lipid-lowering therapy, recommended LDL-C targets
are rarely achieved. A large body of evidence supports the
eﬀectiveness of intensive statin therapy in older patients.
However, concerns that safety may be a particular issue
in an older population appear largely unfounded, so long
as known issues (e.g., drug-drug interactions) are taken
into consideration. If current lipid-lowering guidelines are
followed and older patients are treated to appropriate LDL-
C goals, the likelihood of CV events will be signiﬁcantly
reduced in this high-risk population.
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